Avalo Therapeutics(US:AVTX)2025-11-06 12:02Clinical Trials - Completed enrollment in the Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa, with topline data expected in mid-2026[5] - The LOTUS trial includes approximately 250 adults to evaluate the efficacy and safety of AVTX-009 with two dosing regimens compared to placebo[6] Financial Performance - Net loss for Q3 2025 was $30.6 million, compared to net income of $23.0 million for Q3 2024, with a significant change in other expenses[7] - Basic and diluted net loss per share for Q3 2025 was $2.19, compared to basic net income per share of $0.98 for Q3 2024[7] - Research and development expenses for Q3 2025 were $13.6 million, an increase of $4.1 million from Q3 2024, driven by costs related to the LOTUS trial[6] - General and administrative expenses for Q3 2025 were $5.6 million, an increase of $1.3 million from Q3 2024, primarily due to stock-based compensation[6] Assets and Liabilities - Cash and short-term investments totaled approximately $112 million as of September 30, 2025, expected to fund operations into 2028[5] - Total current assets as of September 30, 2025, were $113.8 million, down from $138.9 million as of December 31, 2024[8] - Total liabilities increased to $33.6 million as of September 30, 2025, compared to $17.7 million as of December 31, 2024[8] Leadership and Personnel - The leadership team was expanded with key appointments, including Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President of Human Resources[5] Risks and Uncertainties - Avalo Therapeutics may face significant risks and uncertainties that could cause actual results to differ from forward-looking statements[15] - The company relies on key personnel and is subject to regulatory risks that may impact its operations[16] - Economic and market risks, including geopolitical tensions such as the war in Ukraine and the Middle East, could affect Avalo's performance[16]